Preview

User

Not a user? Register with this site Forgot your password?

Russian Journal of Geriatric Medicine

Advanced search

Submissions

Online Submissions

Already have a Username/Password for Russian Journal of Geriatric Medicine?
Go to Login

Need a Username/Password?
Go to Registration

Registration and login are required to submit items online and to check the status of current submissions.

Start submission
 

Author Guidelines

Authors Guidelines

I. General Provisions

II. Article Types

III. Author, Affiliation, Title, Abstract, Keywords

IV. Full Text

V. Tables and Figures

VI. Formulas, Equations, and Symbols

VII. References

VIII. Additional Information

I. General provisions

Authors guarantee that their manuscript complies with the the Journal’ aims and scope, its editorial and ethical policy and the requirements of the public Offer.

The manuscript is submitted after registration on the website with the following documents uploaded:

  1. A single complete Manuscript file in MS Word format, which contains the title of the work, abstract, full text, figures and tables, list of references
  2. Possible additional files: high-resolution illustrations; research data or algorithms that facilitate the reproducibility of the study
  3. Cover letter with information about the article in MS Word text format
  4. scan of the printed Cover letter signed by all authors (as a single file in pdf format)
  5. scan of the Potential Conflict of Interest Form (download the form). The original must be filled out and signed by EACH author separately (the journal reserves the right to publish this scan as an online appendix to the published article).

The Journal communicates with the authors' collective exclusively through the corresponding author. The corresponding author is obliged to respond to any requests from the Journal within 10 working days. In the absence of a response from the corresponding author within 30 calendar days, the manuscript is withdrawn from consideration. The corresponding author must have a minimally filled ORCID in English and a corporate email address (possibly in addition to personal).

II. Types of articles

Expert consensus/Clinical (guidelines)

This type of article involves the development by experts of conclusions, protocols and recommendations regarding diagnostic, therapeutic or rehabilitation methods in constantly updated and sometimes controversial views on a particular range of clinical topics and issues. There are several expert consensus technologies for this. Among them, the Delphi method has proven itself the most effective and is most often used (see below).

Such conclusions and recommendations have different options, depending on the level of expertise, interdisciplinary involvement, level of evidence and other base, decision-making method, regional or international validity, as well as other factors.

This type of publication in the Journal is, as a rule, the result of close cooperation between the Journal and the Russian Association of Gerontologists and Geriatricians, as well as other professional organizations.

Recommended guidelines:

Clinical Trial Protocols

This type describes the organization and plan of a clinical trial, including the study objective(s), design, methods, outcome measures, and statistical analysis plan.

Typical requirements:

  • 3000-3500 words
  • ≤5 tables and/or figures
  • 50-75 references in the Literature
  • Structured abstract
  • The title should end with a colon and contain “Clinical Protocol”
  • Registration of the protocol in a registry (e.g., https://clinicaltrials.gov/) with the appropriate number
  • SPIRIT guidelines should be used in preparation and reporting.

Systematic reviews and meta-analyses

This type is a systematic critical analysis of the literature and data sources relevant to clinical topics, focusing on factors such as cause, diagnosis, prognosis, therapy or prevention, and further synthesis of the data to answer the stated research question or hypothesis. The tend to focus on a very specific rather broad subject.

All articles or data sources should be searched and systematically selected for inclusion and critically appraised, and the search and selection process should be described in the Methods section. For each article or data source, the specific type of study or analysis, population, intervention, exposure, and tests or outcomes (to ensure homogeneity of the sources reviewed) should be described.

The number of sources should be in the order of 50–80. They should be as current as possible (in particular, include the current/last 2–3 years). Ideally, the search should be conducted within a few months prior to manuscript submission. Authors of meta-analyses of clinical trials should provide the PRISMA flow chart and checklist.

Authors of meta-analyses of Observational studies should provide the MOOSE flow chart and checklist.

Recommended guidelines and resources:

Narrative reviews

Review articles, as a rule, are initiated by the editors.

Reviews that lack scientific novelty, are written in the format of lectures, generalizing known facts, and are supported by unpublished cases from the authors' practice will not be accepted.

Although this type of article assumes a free organization of the main part, the Journal requires that it be clearly structured and have a multi-level system of subheadings (especially in the main part). Reviews written in continuous text are not accepted.

The Journal establishes the following 3 mandatory sections for the review:

  1. Introduction: a brief overview of the topic (what is known, possibly controversial); justification for the purpose of writing the manuscript (what is its relevance, novelty, necessity/demand); possible formulation of the hypothesis to be proven; search strategy (what databases, keywords were used and for what years)
  2. Main part: analysis and discussion of the literature, according to the logic and structure of the author. This part must have a structure and subheadings. The main part written in continuous text for review will not be accepted.
  3. Conclusion: main findings; possible limitations of this analysis; clinical significance; recommendations for future research

Since this type is not expected to retell known provisions, but to analyze and synthesize current data, authors are advised to present this as clearly as possible (through visualization using tables and figures). When using borrowed images, they must be properly cited, and if they are taken from sources not distributed under a CC-BY license, they must contain the note “used with permission of the copyright holder”.

As stated above, reviews in which the authors use data (including images) from their own unpublished studies are not accepted. As an exception, in such a situation, authors may be advised to place this data in the Mendeley Data repository (where posting is free, the process takes a few minutes, and authors receive a free DOI number). Then such data can be used and cited in the review as preprints.

The article can be up to 6 thousand words. A structured abstract is required (with at least 3 sections described above). The title should end with an indication of the article type. Allow up to 5 Tables/Graphs. References - at least 40-60 sources, which should contain publications of the current year and especially the last 3 years.

When reviewing this type of article, the Journal recommends using the SANRA checklist.

Original research/articles

Intended for presenting original unpublished research results that enrich clinical practice with their novelty and can subsequently be reproduced and generalized (based on the study design and detailed description of methods specified in the manuscript). Original research has many types and formats, depending on the purpose, design and other characteristics. For example, they include short communications, prognostic and experimental studies, ansurveys, and randomized controlled trials (RCTs). For the convenience of the authors, original studies are divided into categories below, depending on their presentation format within the framework of existing international guidelines and established practice and sections of the Journal.

The formal structure of the full text and abstract of "Original Research" should correspond to the chosen study design (EQUATOR Network guidelines). Most often, the structure has the following sections: Introduction, Objectives, Materials and Methods, Results, Discussion (where the Conclusions section is acceptable). It is recommended to use subheadings (e.g. in the Methods section, where inclusion/exclusion criteria, description of the intervention, statistical methods, etc. are often highlighted, or in the Discussion section, where the novelty, clinical significance, limitations of the study and recommendations for subsequent ones should be formulated, and most importantly, if possible, this study should be compared with existing Russian or foreign ones). In this type of article, the "Objectives" section should clearly formulate the research question or hypothesis.

For interventional studies, the Methods section should be as detailed as possible, according to the TIDieR-Checklist and the corresponding guideline.

For diagnostic/prognostic studies (a prospective study designed to develop, confirm, or update the diagnostic or prognostic accuracy of a test or model), the STARD and TRIPOD guidelines should be used.

For randomized controlled trials (RCTs), the relevant CONSORT checklist and its variants/extensions should be used (in particular the guidelines for RCTs with non-pharmacological interventions, see the next section "Clinical Trials").

For experimental animal studies (a type of study that is less welcome in the Journal), authors should consider the design and reporting of questions according to the ARRIVE guidelines. A detailed explanation and the corresponding checklists are available on the ARRIVE resource portal.

For all clinical and experimental studies where only one sex is investigated, it is worthwhile to evaluate the appropriateness of reflecting this in the manuscript title and manuscript sections, according to the SAGER check list.

Short Communication/Pilot Study

This is a short report that may present:

  1. Results of pilot studies
  2. Preliminary results of a study with only tentative conclusions before the study is completed
  3. Replication studies using known protocols that partially expand on the understanding of the question of previously published studies
  4. Studies with negative results on the topics that are a priority for the Journal.

These manuscripts should be no more than 2,000 words long, may have an unstructured abstract, structured text, 1-2 tables, 1-2 images, and a mandatory list of references.

When planning, conducting, and writing the most typical topic for a short communication, “feasibility assessment…”, the recommendations of “How We Design Feasibility Studies” should be used (which considers 8 feasibility criteria and often adds a 9th one, “safety”).

Guidelines for reporting/ submitting “Pilot Studies”

Surveys/ Questionnaires

Manuscripts containing survey data, such as studies involving patients, clinicians, the public, or other groups, should report data collected as far back as possible, ideally within the past 2 years. Survey studies should have a sufficient response rate (typically at least 60%) and appropriate nonresponse characteristics to ensure that nonresponse bias does not compromise the validity of the results. For most surveys, such as those conducted by telephone, in-person interviews, mail, email, or online forms, authors are encouraged to report survey outcome measures using standard definitions and metrics such as those suggested by the American Association for Public Opinion Research. In addition, authors should submit the survey instrument, if possible, as a supplemental file that may be considered for publication as an online appendix to the article. Depositing raw data and algorithms in public repositories is also encouraged.

Recommended guidelines and resources:

Clinical Controlled Trials

This type recommends following a specific type of EQUATOR Network guidelines (particularly the CONSORT guidelines), pre-registering the study protocol (e.g., on clinicaltrial.gov), and posting research  data  in public repositories.

Randomized clinical trial: a study in which participants are prospectively assigned to an intervention or comparison group to examine a causal relationship between the intervention and an outcome. Interventions may include, in addition to medication, surgical procedures, devices, rehabilitation, dietary interventions, changes in the patient care process, etc.

Non-randomized controlled trial: a study in which groups or populations are prospectively assigned to examine the effectiveness or efficiency of an intervention, but in which assignment to the intervention occurs through self-selection or administrator selection rather than through randomization. Control groups may be retrospective, parallel, or both. This design is sometimes called quasi-experimental. TREND guidelines should be used in this type of trial. If retrospective data involve disclosure of patient identities when they are released to third parties for analysis, the Local Ethics Committee should provide the  appropriate approve. If no such decision is made, the authors must declare that they have obtained anonymized data that do not allow identification of patients.

Control types. The paper must clearly indicate the type used:

  • baseline control
  • placebo control
  • active control
  • sham-controlled
  • control based on archival statistics (historical control)

In the case of using "active control" (existing therapy or rehabilitation methods), it is not enough to indicate "standard treatment/ intervention". It shall be described in detail, as in the main group.

Recommended guidelines:

Case report, case series

This type of article is not a priority for the Journal. As an exception, only cases of innovative or unexpected interventions or outcomes that have high clinical significance and are unique for world practice (e.g., description of the development of unregistered or rare adverse reactions when using drugs) are considered. Such an element of uniqueness or novelty should be justified by an appropriate literature search and analysis and reflected in detail in the Introduction and Discussion sections.

Due to the clinical significance of such publications for public health (especially in the case of adverse reactions), the Journal has the right to duplicate such articles in specialized Russian and foreign journals (e.g., Safety and Risk of Pharmacotherapy).

Case reports in the lecture format demonstrating known medical interventions or outcomes are not accepted for consideration.

As a rule, this type of article includes a discussion of the tactics of managing a clinical case, taking into account the ideas about this type of pathology.

Mandatory elements of this publication:

  • a serious review of the literature to justify, for example, an innovative method that has shown high efficiency, or an adverse reaction observed for the first time after drug or device intervention
  • a detailed picture of the patient's observation from the moment of admission to the clinic until discharge with the desired visualization (e.g., in the form of figures and tables)
  • statement on obtaining informed consent from the patient (or the legal representatives) for publication in the journal. If the patient cannot be identified from the medical history and photographs provided, then this statement should indicate that informed consent is not required for these reasons.

The Journal does not require authors to provide a copy of the completed consent form, or that the consent form meets any standards. However, for the convenience of authors, the Journal provides a table of the most frequently used points in this consent.

The article should contain no more than 35 thousand words. The expected volume of literature sources is at least 15-30.

The Journal does not recommend using the phrase "literature review" in the title of the article, since a serious analysis of the literature is implied to justify  the uniqueness of the case and its relationship with existing practice and "literature review" is not the prime aim of case report.

Recommended guidelines:

Commentary to a published article / Response to a comment

Comments are usually readers' critical opinions on the scientific, clinical or ethical aspects of previously published studies or corresponding interpretations and other comments from readers. It is recommended to formulate them clearly in points (no more than 11).

Comments are accepted only for articles published no later than 2 months from the date of their publication. When deciding on publication, preference is given to comments on articles marked "Editor's Choice". Comments accepted by the editorial board are, if possible, published together with the response of the authors of the original article in the same issue. As an exception, a comment and a response to it can be published in a different issue. Only one round of comments and replies is allowed, without continuing the discussion in subsequent issues of the journal.

Other rules:

  • An abstract is not required
  • If there are several comments in the text, they should be numbered and, if possible, a subtitle should be provided for each
  • The Comment Title uses the original title of the article being commented in quotation marks, to which the phrase with a colon “Comment on the article: ...” is added at the beginning, then only the first author and the title of the article are indicated.
  • The Title of the Response to a Comment uses the title of the comment with the addition at the beginning “Response to the comment ...”.

III. Author, affiliation, title, abstract, keywords

Author:

  • Full name is presented in English as “Tkacheva O.N.”
  • It is desirable to indicate the ORCID for each author
  • The spelling of the author's name must correspond to the ORCID variant
  • The ORCID of corresponding author must be filled as completely as possible
  • It is desirable for the corresponding author to indicate (add) a corporate email address

Affiliation:

  • Use official names as registered in ORCID/ ROR/ Scopus profiles

Article title:

  • Be clear and concise:

- The title should be no more than 13 words (120 characters) and understandable to all participants in the geriatric chain, researchers in the field of aging, related sciences and bordering specialties

- Numbers, if they appear at the beginning of the title, should be written in full (not in digists)

- Only commonly used abbreviations in all specialties, understandable to specialists in any field (e.g., “DNA”) are allowed (please check Mesh terms if in doubt)

  • Be self-contained and specific:

- The title should be specific and reflect key aspects of the study, such as the purpose (research question/hypothesis), the parameters to be assessed (e.g., population, intervention, disease, outcome, etc.)

- Avoid general phrases ( e.g. “current approaches”).

  • Look for structure and SEO:

- The first part of the title usually reflects the purpose or hypothesis of the study

- The second part of the title, if acceptable, should reflect the type or design of the study (e.g., randomized controlled trial, review, case report, etc.)

- Include at least 2 keywords/terms in the first 40 characters (5-6 words) to improve search engine optimization

- Use terms from the MeSH (Medical Subject Headings) thesaurus to improve indexing

  • Follow ethical requirement:

- Avoid jokes, rhetoric, declarative and interrogative formulations (which are acceptable for «expert opinion»)

- The title should be neutral and not contain value judgments

- It is advisable to use the international nonproprietary name (INN) instead of commercial names of drugs

- If only one sex of animals or people is used in a preclinical/clinical study, which may affect the results of the study, it should be assessed whether gender should be reflected in the title, in accordance with Chapter IV of the ICMJE recommendations

Abstract (maximum 350 words):

  • No citations or hyperlinks
  • Abstract is structured according to the selected type/design/GUIDELINES OF THE EQUATOR network (if used)
  • Introduction justifies the relevance of the topic and the study
  • Selected methods correspond to the stated purpose and specify the research design
  • No discrepancies between the abstract and the sections of the manuscript, and no statements or conclusions in the abstract that are not in the full text
  • The abstract is clear and self-sufficient without reading the manuscript
  • No declarative, parasitic scientific words and phrases that do not carry much meaning and worsen search engine optimization (e.g., “in this work, the authors tried to conduct a study to answer the current question ...”)
  • Thematic words are found in the first sentences of the abstract, especially in phrases (for better SEO)

Keywords:

  • From 3 to 10 words / phrases. Most of the keywords should be included in MeSH (Medical Subject Headings)
  • For verification, it is recommended to use free resources: https://meshb.nlm.nih.gov and https://meshb.nlm.nih.gov/MeSHonDemand

IV. Full text of the article

The text of the publication should include

Requirements for typesetting and arrangement of text:

  • File with material - in OpenOffice, Microsoft Word or RTF document format.
  • The main text is typed in Times New Roman, font size (font size) of 12 points
  • All illustrations, graphs and tables are located in the appropriate places in the text, and not at the end of the document.
  • The text is well structured using two or three levels of subheadings
  • For the title of the article - bold font, font size 18. For the first subheadings - font size 16. For the second level - 14 and italics
  • The text meets the stylistic and bibliographic requirements described below
  • The paragraph indentation should be the same throughout the publication at 1.25 cm
  • (breaking the paragraph indentation with spaces and the Tab key is not allowed)
  • The page numbers are continuous (the first page is numbered) at the bottom, centered
  • All words within a paragraph are separated by only one space
  • There are no spaces before the punctuation mark, and one space after the punctuation mark
  • Underscores and spaced lines as highlights are not allowed
  • The text is typed without hyphenation (including the need to disable the automatic hyphenation mode) and aligned to the width of the strip (in the text typesetting program, it is necessary to disable the automatic hyphenation mode) and remove forced hyphenation).
  • Footnotes are typed using the automatic word processor
  • Footnotes are numbered per page (Arabic numerals, regardless of the intended formatting)
  • The maximum length of the manuscript, including references, tables and figures, is 12 pages for original articles, 15 pages for reviews / clinical lectures and 6 pages for a clinical case description / short communication.

Body of the text

The text should be well structured and have a reasonable system of multi-level subheadings, according to the recommendations of the journal or the existing EQUATOR Network recommendations for the existing design or type of article.

If the basic structure of IMRAD (Introduction, Methods / Materials and Discussion) or similar is available, it is recommended to consider the following design aspects, especially for original research.

Relevance (or Introduction):

  • If necessary, brief information about the question being studied
  • Demonstrate the clinical or scientific importance of the question being studied
  • Other justification for the purpose (possibly methods) of the study

Purpose:

  • Clear (e.g., “To determine whether…”).
  • If more than one purpose is considered, the primary and secondary purposes or additional objectives should be stated.
  • If a null hypothesis was tested, this should be stated

Methods

They typically describe the following elements, where it is recommended to include subheadings:

  • Design
  • Inclusion/exclusion criteria
  • Study setting
  • Patients
  • Interventions

Study design:

  • Basic study design (e.g. randomized clinical trial, cohort study, cross-sectional study, case-control study, case series, meta-analysis), and possibly the EQUATOR Network guideline used
  • Study years, duration of follow-up, and date of current analysis if data are older than 3 years
  • If applicable, the title of the study should be provided (e.g. “The role of comorbidities in risk stratification of postoperative complications in abdominal surgery STOPRISK”)
  • Where appropriate, information on whether observers were blinded or blinded to patient groups or their allocation, particularly in the case of subjective measurements.

Study setting

Particularly in the case of a clinical trial of a non-pharmacological intervention, the results, reproducibility and subsequent clinical applicability depend largely on the centre conducting the study (its expertise, staff experience, standards, patient volume, etc.). For this reason, it is important to detail the important circumstances of the study setting and, where possible, to provide the names of the participants. institutions.

Participants (Patients):

  • Clinical disorders
  • Important selection criteria and key sociodemographic characteristics of patients
  • Number of participants and how they were selected (inclusion/exclusion criteria), including the number of otherwise eligible individuals who were approached but declined to participate
  • If matching was used for comparison groups, the characteristics to be compared
  • In observational studies, the proportion of participants who completed the study
  • In interventional studies, the number of patients who withdrew from the study due to adverse events
  • For selection procedures, the type of sample.

Interventions:

  • Maximum detail, according to the TIDieR-Checklist and related manual
  • Description of the medical devices used (including model, manufacturer, country of manufacture)
  • Nomenclature (not proprietary) names of drugs

Results

  • The order of presenting results is the same as the order of describing the methods
  • Primary outcomes and their measures
  • Estimates of baseline and final sample data
  • Absolute values ​​(e.g. increase, decrease, or absolute differences between groups) as well as effect sizes and associated measures of uncertainty such as confidence intervals (CI)
  • Means and standard deviations for normally distributed data, and medians and ranges or interquartile ranges (IQR) for data that are not normally distributed
  • Avoid reporting solely the results of statistical hypothesis tests such as P values, which fail to convey important quantitative information
  • In most studies, P values ​​should follow reports of comparisons of absolute values ​​or measures of uncertainty (e.g. 0.8%, 95% CI -0.2% to 1.8%; P=0.13)
  • P values ​​should never be reported alone, without the data being compared. Approaches such as number needed to treat per unit benefit may be mentioned when appropriate. Relative risk measures (e.g., relative risk, hazard ratios) may also be reported and should include CIs
  • Studies of screening and diagnostic tests should report sensitivity, specificity, and likelihood ratios
  • If predictive value or accuracy is reported, prevalence or pre-test probability should also be reported.
  • All randomized clinical trials should include intent-to-treat and adverse event analyses
  • All surveys should include response rates
  • The journal encourages pre-posting of all raw research data in public repositories that assign a DOI number (e.g., Mendeley Data)

Discussion:

  • Critical and objective examination of the study/interpretation of results (i.e., discussion of results in comparison with previously published studies)
  • Examination of the research question or hypothesis (also in terms of comparison with results from other studies)
  • Discussion, not replication of results
  • Novelty, limitations/unaccounted for potential biases of the study, and recommendations for future studies

Conclusions/findings

  • Only those conclusions of the study that are directly supported by the results.
  • Equal attention to positive and negative results of equal scientific value
  • Relevance and clinical significance without speculation or overgeneralization
  • Generalization, if necessary, whether further research is required before the information can be used in clinical settings.

In-text citation

References are listed as they appear in the text. The titles of all cited articles are required (see below for formatting of the reference list). All articles in the reference list must be cited in the text and, conversely, all references cited in the text must be included in the reference list. Citations are given in square brackets – [1], [2-5], etc.

When citing preprints, it is advisable to emphasize in the full text, at the discretion of the author, that this is a preprint, e.g.: “… according to P.M. Ivanov et al. [25] (preprint)…”.

Abbreviations and acronyms

All abbreviations used in the text (even "commonly accepted") should be expanded upon first mention. Avoid using abbreviations in headings without first expanding them in the full text.

It is recommended to use no more than 7 abbreviations per article to improve the readability of the text. In case of a larger number, a list should be placed before the beginning of the full text.

If an abbreviation was introduced in the title or abstract, it should be expanded again in the full text upon first mention.

It is recommended to use the MeSH thesaurus to check the correctness of common abbreviations.

V. Tables and Figures

All tables and figures should be numbered with Arabic numerals and have clear titles and captions to the tables.

Please make sure that the data in the tables correspond to the figures in the text, and do not simply duplicate them.

Graphs must be labeled on the ordinate and abscissa with the measured parameters or variables, units of measurement and scale.

Units of measurement must be metric and correspond to the International System of Units.

At the initial review stage, all images and tabular material must be inserted at the place of reference in the main text of the file. References to illustrative material in the text should be formatted as "(Fig. 1)" and "(Table 1)".

Color or black and white images must be contrasting and easily readable. Preference is given to vector formats (eps). Raster formats (jpg, tif), as well as pdf, are allowed.

As part of the inclusive policy, the Journal reminds that about 7% of the population suffers from various forms of color blindness. For this reason, all graphs and figures must be made taking into account their full perception by those suffering from this disorder/the possibility of full perception when converted to a black and white image (e.g. by introducing different numbers/letters/symbols for curves or areas represented in different colors). If this rule is not followed, manuscripts that have received generally positive reviews will be returned for revision.

Other recommendations:

  • All illustrations are made in the color modes "RGB" or "Grayscale"
  • Any graphs and diagrams (with numerical data) are recommended to be made using Microsoft Excel (versions 2003 and later) and placed in the document with the link preserved or provided as separate files (mark the places of occurrence in the text of the manuscript), XLS, XLSX format.
  • In cases where third-party spreadsheet processors and specialized programs for plotting graphs and diagrams are used, provide a screen copy of the resulting file only in extreme cases – the result should be output to a virtual printer in pdf format (with the pre-installed “Printing quality” profile) or another vector format (e.g. EPS, SVG, AI).
  • Raster illustrations (e.g. photographs, scanned drawings, screen copies) should also be provided in addition to embedded elements and as separate files in JPEG2000, TIFF format with a resolution of at least 300 dpi, without compression
  • Each drawing is provided as a separate file, where the file name should reflect the structural numbering of the illustration in the text (e.g.: Figure 1.21 – file name: figure 1–21.tif)).
  • In case of using files of additional formats (for example: xls-files, cdx-files, ppt-files, visio-files, etc.), they should be provided in the original format with a separate file (in the format: *.rtf, *.doc, *.docx) describing the nuances
  • Authors are advised to evaluate the justification for using a pie chart (or replacing it with a line chart, as a more objectively reflective value) before submitting a manuscript
  • The journal does not welcome the use of a colored background in graphs
  • The journal does not welcome shadows in line charts, as well as often inappropriate 3D graphics for two-dimensional images
  • “Before” and “After” photographs should be taken under the same lighting conditions and camera distance from the object

VI. Formulas, equations and symbols

  • external mathematical formulas (formatted on a separate line) should be typed in the MathType program
  • general (by default in the program) font settings, symbol sizes and their placement should be used for formulas typed in MathType
  • numbers in formulas should be typed in roman font; letter designations of quantities (symbols) for which Latin letters are used, in italics; abbreviated mathematical terms (for example: sin, cos, lg, lim, max) - in roman font; letters of the Russian and Greek alphabets (both in the formula itself and in indices) - in roman font; indices - in roman font, for example Ncon (i.e. Nfinite), Cmax, Scp; there is no period at the end of the index; designations of chemical elements - in Roman font.
  • a set of formulas from composite elements, where part of the formula is a table or text, and part is a formula itself, is not allowed
  • it is not allowed to insert formulas into the text as graphic elements (figures)
  • simple mathematical and chemical formulas (for example, a2 + b2 = c2; H2SO4) and single variables or designations must be typed in text mode without using the MathType program
  • the transfer of the equation is allowed after the equal sign (=), plus (+) or minus (–), multiplication (×), and the sign at the beginning of the next line is repeated
  • an explanation of the meaning of symbols and numerical coefficients should be given directly below the formula (equation) in the same sequence in which they are given in the formula (equation)
  • formulas and equations in the article are numbered with ordinal numbering within the entire manuscript with Arabic numerals in parentheses and in the far right position on the line, even if there is only one formula in the text, for example:

A = a + b(1)

  • references in the text to the ordinal numbers of formulas and equations are given in brackets in Arabic numerals
  • decimal places in numbers in the Russian text are typed separated by commas (for example, 0.25), in English - the opposite (0.25).

VII. References

The authors are responsible for the correctness and completeness of the data provided in the list of references.

The journal adheres to the adapted version of the international style "AMA" (11th edition of the American Medical Association).

In the journal, in contrast to the AMA style, it is customary to indicate initials using a period.

An example of square brackets, initials with a period (e.g. Ivanov V.V.).

DOI

All references to journal publications must contain a DOI (Digital Object Identifier). The presence of a DOI for an article should be checked on the website http://search.crossref.org/ or https://www.citethisforme.com. To obtain a DOI, enter the title of the article in English in the search bar. The latter site, in addition to the DOI, automatically generates a correctly formatted bibliographic spelling of the article in English in the AMA citation style. The vast majority of foreign journal articles and many Russian-language articles published after 2013 are registered in the CrossRef system and have a unique DOI.

The journal uses the following DOI format (without https:): DOI: 10.1136/annrheumdis-2012-202021.

It is prohibited to transfer part of the DOI to the next line in your manuscript (you cannot break the sequence of characters in the DOI).

A complete list of all authors must be provided in each bibliographic record. Please put "et al." or "et al." after the third name if the cited article has more than 4 authors.

Abbreviated journal titles must match the Medline catalog. If the journal is not indexed by Medline, its full title should be indicated.

Other recommendations:

  • When citing an Internet resource, it is necessary to indicate the last date of the author's access to it in a uniform British English style (e.g., Accessed 18 March, 2023)
  • It is not allowed to indicate the PMC/Medline identifier
  • It is acceptable to use footnote references instead of a bibliography (for citing non-scientific literature: acts, orders, Internet resources, etc.). Then all footnote references should be numbered consecutively
  • Most article types use current, international references without a predominance (unless there is a logical justification for this) of national ones and those that do not have an English version (e.g., orders)
  • The number of references in the article corresponds to the type of article and the journal's recommendations
  • For preprints, there is a note that this is a preprint (both in the Reference List and in the full text)

Examples:

  • Journal articles with DOI

Author A.A., Author B.B. Article title. Journal. Year; Volume (Number): s–s.

Dixon W.G., Bansback N. Understanding the side effects of glucocorticoid therapy: shining alight on a drug everyone thinks they know. Ann Rheum Dis. 2012; 71(11): 1761–4. DOI: 10.1136/annrheumdis-2012-202021.

  • Journal articles without DOI

Meeker D., Linder J.A., Fox C..R, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial. JAMA. 2016; 315(6): 562-570. Accessed June 18, 2019. https://www.jamanetwork.com/journals/jama/fullarticle/2488307

  • Books, monographs

Jenkins P.F. Making sense of the chest x-ray: a hands-on guide. New York: Oxford University Press; 2005 194p

Puig-Samper M.A., Ruiz R., Galera Andres A., eds. Evolucionismo y cultura darwinismo en Europae Iberoamerica. Aranjuez (Spain): Ediciones Doce Calles; 2002 407 p.

Adkinson N.F. Jr, Bochner B.S., Burks W., et al, eds. Middleton's Allergy: Principles and Practice. 8th ed. Saunders; 2014.

Kwon D.S., Walker B.D. Immunology of human immunodeficiency virus infection. In: Paul WE, ed. Fundamental Immunology. 7th ed. Lippincott Williams & Wilkins; 2012:chap 42.

  • Regulations, orders

Veterans Hearing Loss Compensation Act of 2002, Pub. L.No. 107-9, 115 Stat. 11 (May 24, 2001).

Healthy Children Learn Act, S. 1012, 107th Cong., 1st Sess. (2001).

Cardiopulmonary Bypass Intracardiac Suction Control, 21 C.F.R. Sect. 870.443 (2002)

  • Conference materials

Harnden P., Joffe J.K., Jones W.G., editors. Germ cell tumors V. Proceedings of the 5th Germ Cell Tumor Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002

Christensen S., Oppacher F. An analysis of Koza’s computational effort statistics for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer; 2002 p. 182-91.

  • Dissertations

Borkowski M.M. Infant sleep and feeding: a telephone survey of Hispanic Americans [dissertation]. Mount Pleasant (MI): Central Michigan University; 2002

  • Internet resource

The date of the last access must be indicated

Charlton G. Internal linking for SEO: examples and best practices. SearchEngineWatch. Accessed February 10, 2016. https://searchenginewatch.com/sew/how-to/2428041/internal-linking-for-seo-examples-and-best-practices

  • Patent

Pagedas A.C., inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498 2002 Aug 1

  • Preprint or manuscript accepted for publication

Before submitting a manuscript to the Journal, it is necessary to check whether a preprint or a manuscript accepted for publication has been released and replace it with the details of the regular publication. The preprint or accepted manuscript should be indicated in square brackets. Examples:

  • Bloss C.S., Wineinger N.E., Peters M., et al. A prospective randomized trial examining health care utilization in individuals using multiple smartphone-enabled biosensors. [Preprint]. Posted online October 28, 2015. bioRxiv 029983. DOI: 10.1101/029983
  • Collins-McMillen D., Stevenson E.V, Heon Kim J., et al. HCMV utilized a nontraditional STAT1 activation cascade via signaling through EGFR and integrins to efficiently promote the motility, differentiation, and polarization of infected monocytes. J Virol. [Accepted manuscript]. Published online October 11, 2017. DOI: 10.1128/JVI.00622-17
  • Datasets in the public repository:
  • NIKOLAEVA, Mariya; Neymark, Mikhail; Momot, Andry. Data from: Bleeding disorders associated with severity of respiratory failure in COVID-19 patients. 2023. Mendeley Data, V1, doi: 10.17632/2z3dmg4y5f.1
  • Cutter AD, Gray JC. Data from: Ephemeral ecological speciation and the latiudinal biodiversity gradient. Evolution. 2016;70(10):2171-2185. Dryad Digital Repository. Deposited August 17, 2016. doi:10.5061/dryad.734v9
  • Francuzik W. Data from: Skin microbiome in atopic dermatitis: 16S gene sequence data. figshare. 2016. doi:10.6084/m9.figshare.4028943
  • Online supplements to the article
  • Meeker D, Linder JA, Fox CR, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial. Supplement 1. Study protocol and changes to analysis plan. JAMA. 2016;315(6):562-570. Accessed June 18, 2019. https://www.jamanetwork.com/journals/jama/fullarticle/2488307

VIII. Additional information

  1. Authors' contributions and information about the authors
  2. Ethical and other statements
  3. Access to research data and online supplements

 

  1. Authors' contribution

It is necessary to reflect the level of participation of each author and ensure that each author meets the following 4+ ICMJE criteria:

  • Substantial contribution to the conception OR design of the work; OR collection, analysis OR interpretation of data from the work

AND

  • Writing a draft of the manuscript OR revising it critically for important intellectual content;

AND

  • Final approval of the version to be published;

AND

  • Agreement to be accountable for all aspects of the work and to ensure that any concerns related to the accuracy or integrity of any part of the work, if any, will be appropriately addressed by them.

In addition to responsibility for specific parts of the work, the author should be able to identify which co-authors performed other specific parts of the work. In addition, the authors should be confident that the contributions of all co-authors have been ethically sound.

The authors may indicate any other relevant contributions to the work. The Editorial Board encourages, but does not require, detailing the contributions of each author, or the use of any international system (e.g. 14-item CRediT , Contributor Roles Taxonomy classification). The corresponding author is responsible for coordinating the contribution described by all authors.

Examples:

  • Author contribution: All authors confirm the compliance of their authorship, according to ICMJE criteria. In addition, Petrov P.P. performed statistical analysis of the results and its visualization.
  • Author contribution: All authors confirm the compliance of their authorship, according to ICMJE criteria with the following additional contribution. Helena Smith: conceptualization, development of research methodology, work with software. Anna Falcone: data curation, preparation of the manuscript draft. Mandy Green: visualization, conduct of research. Arina Brown: scientific supervision of the study. Amni King: software, data validation. Aron Hang: manuscript editing.

Author information

This is an optional block, as this information is contained in the authors' ORCID profile. However, it can be published at the authors' request.

 

  1. Ethical and other statements

2.1. Acknowledgments

  • It is necessary to indicate the specific names of people, companies and organizations, refraining from irrelevant and unspecified contributions (e.g., thanks to your parents, organization, editorial board as a whole, without specifying this contribution, or to some anonymous reviewers of the journal)
  • Expressions are made to Contributors who contributed to the research and writing but do not meet all the authorship criteria (e.g., they only performed literature analysis, visualization or mathematical statistics)
  • Expressions are made to people and organizations that supported the research and writing of the manuscript to one degree or another (e.g., performed additional genetic tests, provided unique equipment / reagents) or partially financed individual stages at the initiative of the authors
  • It is important to indicate the exact name of the organization (with the country)
  • When mentioning someone in the acknowledgments (especially with details of their contribution) it is important to obtain their permission for the appropriate mention. This should be reflected in the cover letter. In case of claims against the Journal from third parties regarding illegal mention by the authors, this responsibility is shifted to the authors and the subject of the article retraction.

Examples:

  • The authors express their gratitude to: Tabletki Rus for providing reagents for gastroscopy; faculty of the Kuban State Medical University, Russia, Associate Professor V.G. Sidorov for histological analysis and Junior Researcher P.V. Petrov for statistical analysis of data; Prof. Ch.K. Ivanova (Faculty of Fundamental Medicine, Filippov Moscow State University, Russia) for critical comments on the final version of the manuscript.
  • We thank the CHERUB cooperative and IciStem consortium for support and continuous discussion of results; staff members at University College London Hospitals NHS Trust, Imperial College Healthcare NHS Trust, and Mortimer Market Centre; Nina Parmahand, Rebecca Matthews, Laura Waters, Helen Brown, Águeda Hernández Rodríguez, Victoria González Soler, and Belén Rivaya Sánchez (Microbiology Department of the Hospital Germans Trias i Pujol, Barcelona, ​​Spain), and Dorien de Jong and Ninée Buchholtz (Translational Virology Group of the Department of Medical Microbiology of the UMC Utrecht, Utrecht, Netherlands).

2.2. Information on external funding

  • A brief list of funding sources that were used to obtain the results presented in the article, as well as the publication process itself (e.g. er, commercial organization, Foundation or government grant, etc.).
  • This section primarily concerns external funding and when the study was initiated from outside (not by the authors).
  • This section should always be: (if there is no funding, it is important to indicate that there was no external funding)
  • In case of a grant, it is important to write the official name of the granting organization and indicate the grant number
  • If a company (especially an instrumental or pharmaceutical one) partially financed a particular stage, then it is necessary to indicate which one.

Examples:

  • Funding. The authors declare that there was no external funding for the study.
  • This study was not supported by any external sources of funding.
  • This work was supported by the Research Foundation Flanders (grant 1861219N to BO and TBM T006116N to JD, FH and ML) and the European Research Council (grant 727674 and 683144 to ML).

2.4. Disclosure of interests

  • An explanation of any potential or actual conflict of interest of the authors. Any affiliations, financial relationships, financial or industry interests in the manuscript in whole or in part, including employment and other commitments, that could lead to concealment or intentional distortion of data or adverse influence on interpretation, are considered a conflict of interest and should be clearly declared as such. Please note that conflicts of interest do not prevent publication.
  • The Editorial Board requires disclosure of interests using the standard ICMJE 13-item form. A scan of the completed and signed forms by each author individually should be attached (preferably as one combined file) to the Cover Letter. Based on the results of the completed forms, the authors' collective forms a final statement on the disclosure of interests. If none of the authors has any, this should also be reported.

Examples:

  • Disclosure of interests. N. Tkacheva is the President of the Russian Association of Gerontologists and Geriatricians (RAGG); A. V. Naumov is the Head of the Executive Committee of the Russian Association of Gerontologists and Geriatricians; N. K. Runikhina is a member of the Presidium of the Russian Association of Gerontologists and Geriatricians. The remaining authors declare no potential conflict of interest.
  • Disclosure of interests. The authors declare no competing interests.
  • Disclosure of interests. RKG has received consultancy fees from ViiV Healthcare and Gilead Sciences, outside of the submitted work. JM-P holds institutional grants or has received educational or consultancy fees from AbiVax, AstraZeneca, Gilead Sciences, Grifols, Janssen, Merck, and ViiV Healthcare, outside of the submitted work. MN has received consultancy fees from Gilead Sciences, outside of the submitted work. AMJW reports grants paid to her institution from CLJI, Gilead Sciences, Janssen, Merck, and ViiV Healthcare, outside of the submitted work; financial support paid to her institution from Virology Education (conference organizer), outside of the submitted work; and non-financial support from ARK diagnostics, outside of the submitted work. EN has received grants from the National Institute for Health Research and GlaxoSmithKline. DP, ALH, CG, MS, MP, LEM, SAG, JT, AA, LEPH, PG, SGE, AJI, JF, and EO declare no competing interests.

2.5. Information on study approval by the local ethics committee.

A full, unambiguous indication of the ethics committee and details of the approving document (number and date) are preferable.

This section is mandatory for interventional studies, even if it is not relevant. In this case, it should say: Not applicable.

Example:

  • Ethics approval. The study was approved by the local ethics committee of the Kuban State Medical University (protocol No. 12 dated 12.03.2019).
  • Ethics approval. The study protocol was approved by the local Ethics Committee of the Shulan (Hangzhou) Hospital (reference number: 20181009).
  • Ethics approval. This study was approved by the Ethical Committee of Hospital Clinic of Barcelona: HCB/2017/0856.
  • Ethics approva The research protocol was approved by the local ethics committee of Ghent University Hospital (joint Ghent-Antwerp protocol 2012_593), the local ethical board for human experimentation of Policlinico di Bari (2770-27/2/19), the protocols of Bambino Gesù Children’s Hospital Rome (1770/2019), and the ethical committee of UMC Utrecht (protocol 16-349). Approval for the use of ‘blood products unsuitable for transfusion’ was obtained with the Red Cross (CG20161219B).

2.6. Informed consent for publication

  • This refers to the information allowing to identify the patient(s).
  • Only in very rare cases, when it is impossible to find legal representatives or the case is extremely important for medical practice, it is possible to publish it, but it is necessary to clarify the lack of consent and indicate that every effort was made to obtain it.
  • The patient's consent usually states that his personal data will be anonymized, which should be done in the manuscript (e.g., part of the face is covered)
  • It is NOT required to provide informed consent to the editor
  • This section is mandatory for all clinical cases. If consent is not required, then indicate: Not required.

Examples:

  • Informed consent for publication. The authors obtained written consent from the patient's legal representatives for the analysis and publication of medical data and photographs.
  • Consent for publication. Written consent was obtained from the patient for publication of relevant medical information and all accompanying images within the manuscript.

2.8. The registration number of the study (protocol)

Please indicate it in a covering letter (e.g., clinicaltrials.gov). If it is available and the manuscript is accepted for publication, the Editorial Board will independently place it between the abstract and keywords.

 

3.0. Data Sharing statement

This statement is welcome especially for randomized clinical trials.

The Editorial Board recommends using the following templates:

  • The data supporting the findings of this study are publicly available: Mendeley Data, V1, doi: 10.17632/2z3dmg4y5f.1
  • Data embargoed due to commercial restrictions The data supporting the findings of this study will be made available in 6 months from the publication date, to enable commercialization of the research findings.
  • Data available upon reasonable request from the corresponding author.
  • The data are not publicly available as may compromise the confidentiality of study participants.

 

Public Offer License Agreement

  1. Subject of the Agreement

1.1. This Agreement is a public offer agreement of the journal "Russian Journal of Geriatric Medicine" with ISSN 2686-8636 (Print) and ISSN 2686-8709 (Online) (hereinafter referred to as the Journal). If the Author(s) (hereinafter referred to as the Licensor) provides the editorial board of the Journal (hereinafter referred to as the Licensee) with their manuscript for publication after the necessary review, editing and proofreading (hereinafter referred to as the Work) in any possible way, i.e. in a handwritten/printed/electronic version, the Licensor automatically accepts the terms of this agreement.

1.2. This agreement is irrevocable (notmay be terminated unilaterally without a court decision).

1.3. Under this agreement, the Licensor grants the Licensee non-exclusive rights to use its Work within the limits stipulated by the agreement for an unlimited period.

1.4. The transfer of rights to use materials from the licensor to the licensee complies with the international license standard CC BY-NC-SA 4.0, which allows third parties to distribute and adapt this work, without the possibility of commercial use, with the obligatory preservation of links to the authors of the original work and the original publication in this Journal.

 

  1. Rights and obligations of the parties

2.1. The licensor of the manuscript guarantees the following:

2.1.1. Compliance of the manuscript with the subject matter and editorial policy of the Journal, as well as its rules for authors (including the provision of the required package of documents).

2.1.2. In case of multiple authors, approval of authorship and delegation of all rights to the corresponding author for sole communication with the Licensee and subsequently with the readership of the Journal.

2.1.3. Compliance with the Journal's regulations and personal responsibility of each author for any aspect of the Work before and after publication.

2.1.4. Bearing responsibility for originality, scientific content and compliance with ethical principles.

2.1.5. The manuscript does not violate anyone's copyright, contains all references to cited authors and publications provided for by the current copyright legislation, as well as images, results and facts obtained by other authors or organizations used in the article.

2.1.6. The manuscript does not include materials that are not subject to publication in the open press, in accordance with current regulations.

2.1.7. The manuscript has not been published anywhere before, has not been sent and will not be sent for publication to other scientific publications without the consent of the Licensor.

2.1.8. When using artificial intelligence tools, the Licensor followed the current policies of the Journal, the user agreement of these tools, and also checked the accuracy, relevance and originality of the generated content.

2.2. The Licensor gives the Licensee its consent to the following:

2.2.1. Providing the use of the Work throughout the world, in accordance with paragraph 1.4, in particular, to use the Work by posting it in whole or in part, including by means of the Journal's website, in various databases and information systems.

2.2.2. The Licensee's revision of the manuscript illustrations, editing the text and translating it into foreign languages.

2.2.3. The Licensee's right to refuse publication, retract or withdraw the published Work, as well as to post corrections or other notices regarding the Work.

2.2.4. Processing in accordance with Art. 6 of the Federal Law "On Personal Data" dated 27.07.2006 No. 152-FZ of their personal data (last name, first name, patronymic, academic degree, academic title, position, place(s) of work and/or study, contact information at the place of work and/or study) for the purpose of publishing the submitted Work in the Journal.

2.3. According to paragraph 1 of this Agreement, the Licensor reserves the following rights:

2.3.1. All patent rights to any process, procedure or product described in the Work.

2.3.2. The ability to publish the manuscript in preprint databases, as well as the original research data in the relevant repositories (for example, Mendeley Data), provided that the Licensor updates the metadata of these databases and repositories after the publication of the Work, where, in particular, it will enter the details of the published Work.

2.3.3. Possibility of posting the final version of the Work in institutional and public repositories (for example, ResearchGate)

 

  1. Liability of the Parties

3.1. The Licensor and the Licensee bear property and other legal liability in accordance with the current legislation of the Russian Federation for failure to fulfill or improper fulfillment of their obligations under this agreement.

 

  1. Final Provisions

4.1. All disputes and disagreements between the parties arising from the terms of this agreement shall be settled by negotiations, and if they are unsuccessful, such disputes shall be resolved in court in accordance with the current legislation of the Russian Federation.

4.2. In all matters not provided for in this agreement, the parties shall be guided by the norms of the current legislation of the Russian Federation.

 

Privacy Statement

Specified when registering the names and addresses will be used solely for technical purposes of a contact with the Author or reviewers (editors) when preparing the article for publication. Private data will not be shared with other individuals and organizations.

 


Publisher: SSFIMT

 

Processing of personal data
supported by NEICON (Elpub lab)